


# Cardiovascular Pharmacology

- **Antiarrhythmic drugs**
- **Drugs in heart failure**
- **Antihypertensive drugs**
- **Antianginal drugs**
- **Antihyperlipidemic drugs**

# Antiarrhythmic Drugs


**Prof. Abdulrahman Almotrefi**



# Learning objectives

*By the end of this lecture, students should be able to:*

- **Understand** definition of arrhythmias and their different types
- **describe** different classes of Antiarrhythmic drugs and their mechanism of action
- **understand** their pharmacological actions, clinical uses, adverse effects and their interactions with other drugs.









**Cardiac Conduction System**

# **CARDIAC CONDUCTION SYSTEM**

- S.A. node**
- Inter-nodal pathways**
- A.V. node**
- Bundle of His and branches**
- Purkinje fibers**




# Electrocardiogram (ECG)




**Electrical and Mechanical Events**

# CARDIAC ACTION POTENTIAL


Skeletal action potential:



Cardiac action potential:




# Fast-Response Action Potential (e.g., ventricular myocyte)






# CARDIAC ACTION POTENTIAL

## Non-pacemaker (ventricular muscle)




# CARDIAC ACTION POTENTIAL

## Pacemaker (SA node)



# Difference between pacemaker and non-pacemaker action potential




# WHAT IS ARRHYTHMIA?

An **abnormality** in the :

■ rate ..... high= tachycardia

low = bradycardia


## Normal Sinus Rhythm



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
60-100 bpm	Regular	Before each QRS, identical	.12 to .20	<.12




# Sinus Tachycardia



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
> 100 bpm	Regular	Before each QRS, identical	.12 to .20	<.12



## Sinus Bradycardia




Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
< 60 bpm	Regular	Before each QRS, identical	.12 to .20	<.12

# WHAT IS ARRHYTHMIA?

An **abnormality** in the :

- rate ..... high= tachycardia  
low = bradycardia
- regularity ..... Extrasystoles  
( PAC, PVC )

## Multifocal PVC's: more than one shape





## Atrial Fibrillation



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
A: 350-650 bpm V: Slow to rapid	Irregular	Fibrillatory (fine to course)	N/A	<.12

# WHAT IS ARRHYTHMIA?

An **abnormality** in the :


- rate ..... high= tachycardia  
  low = bradycardia
- regularity ..... extrasystoles
- site of origin ... ectopic pacemakers
- or disturbance in conduction

# Disturbances in conduction

1st degree AV Block



2nd degree AV Block  
Wenkebach/Mobitz I



2nd degree AV Block  
Mobitz II



3rd degree AV Block





# Therapeutic use of antiarrhythmic drugs

**The ultimate goal of therapy**



**Restore normal rhythm & conduction**



**Maintenance of  
normal rhythm**



**Prevention of more  
serious arrhythmias**

# How antiarrhythmic drugs produce these effects?

- **Slow conduction velocity**
- **Altering the excitability of cardiac cells by prolonging the effective refractory period**
- **Suppressing ectopic pacemaker activity by inhibiting phase 4 slow depolarization**

**CLASSIFICATION  
OF  
ANTIARRHYTHMIC DRUGS**

# Vaughn Williams classification

## CLASS I

**Na<sup>+</sup> channel blockers  
( membrane stabilizing drugs)**

## CLASS II:

**β- adrenoceptor blockers**

## CLASS III:

**Drugs that prolong action potential duration**

## CLASS IV:

**Calcium channel blockers**

# CLASS I



Drugs that block the influx of **Na ions** through **Na channels**



1- decrease the rate of rise of rapid depolarization (Phase 0)

2- decrease phase 4 slow depolarization (suppress pacemaker activity)

(membrane stabilizing effect)



# CLASS I

- **Sub classified according to their effect on action potential duration :**
  - **la** : prolong action potential duration
  - **lb** : shorten action potential duration
  - **lc** : no effect on action potential duration



# CLASS I a


**Ia** : prolong action potential duration

e.g.

**Quinidine**

**Procainamide**

Class IA drugs slow Phase 0 depolarization, prolong action potential, and slow conduction.



# CLASS I a **QUINIDINE**

## Other pharmacological actions :

1- Anticholinergic effect:



Increase conduction through the A.V. node

( risk of ventricular tachycardia )

2-  $\alpha$ -adrenergic blocking effect:



may cause vasodilatation & reflex sinus tachycardia

( seen more after I.V. dose )

3- ECG changes:

- prolongs P-R and Q-T interval
- widens QRS complex

**CLASS I a**

**QUINIDINE**


**Therapeutic uses:**

- **atrial flutter & fibrillation**
- **maintaining sinus rhythm after cardioversion**

# CLASS Ia QUINIDINE

## Adverse effects :

quinidine syncope: episodes of fainting due to **torsades de pointes** (twisting of the spikes) developing at therapeutic plasma levels



# Torsades de pointes

- may terminate spontaneously or lead to



**fatal ventricular fibrillation**

## Ventricular Fibrillation



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
300-600	Extremely irregular	Absent	N/A	Fibrillatory baseline

**CLASS I a**  
**QUINIDINE**

**Adverse effects :**

❖ **Anticholinergic adverse effects:**

- **Dry mouth**
- **Blurred vision**
- **Urinary retention**
- **constipation**

❖ **Hypotension**

- **due to depressing contractility & vasodilatation**

**GIVEN ORALLY ( Rarely given I.V. )**

## CLASS I a

### PROCAINAMIDE

**Similar to quinidine except :**

**1- less toxic on the heart...**

**can be given I.V.**

**2- more effective in ventricular than in**

**atrial arrhythmias**

**3 - No anticholinergic or  $\alpha$ -blocking actions**



**CLASS I a**  
**PROCAINAMIDE**

**Adverse effects:**

- In long term therapy it causes reversible  
**lupus erythematosus-like syndrome**
- Hypotension
- Torsades de pointes
- Hallucination & psychosis

# CLASS I b


- **Shorten action potential duration**

**e.g.**

**Lidocaine**

**Mexiletine**

Class IB drugs shorten Phase 3 repolarization and decrease the duration of the action potential.



**CLASS Ib**  
**LIDOCAINE**

**Therapeutic uses :**

treatment of **emergency** ventricular arrhythmias

e.g. :

- 1 - during surgery
  - 2 - following acute myocardial infarction
- **NOT** effective in atrial arrhythmias
  - **NOT** effective orally (3% bioavailability)
  - given I.V. bolus or slow infusion
  - $t_{1/2} = 2$  hours

**CLASS Ib**  
**LIDOCAINE**

**Adverse effects:**

- hypotension**
- similar to other local anesthetics,  
causes CNS adverse effects such as:**
  - **paresthesia**
  - **tremor**
  - **dysarthria (slurred speech)**
  - **tinnitus**
  - **confusion**
  - **convulsions**



# CLASS Ib

## MEXILETINE

- EFFECTIVE ORALLY

**Therapeutic uses :**

1- ventricular arrhythmia

2- digitalis-induced arrhythmias

$t_{1/2} = 10$  hours

**ADVERSE EFFECTS :**

1- nausea , vomiting

2- tremor , drowsiness, diplopia

3- arrhythmias & hypotension


# CLASS Ic

- have no effect on action potential duration

e.g.

**Flecainide**

Class IC drugs  
markedly slow  
Phase 0 depolarization.




**CLASS Ic**  
**FLECAINIDE**

**Therapeutic uses :**

- **supraventricular arrhythmias**
- **Wolff-Parkinson-White syndrome**
- **very effective in ventricular arrhythmias, but very high risk of **proarrhythmia****
- **should be reserved for resistant arrhythmias**

# Wolff-Parkinson-White syndrome

- Pre-excitation of the ventricles due to an accessory pathway known as the Bundle of Kent.



**CLASS Ic**  
**FLECAINIDE**

**Adverse effects:**

**1- proarrhythmia**

**2- CNS :**

**dizziness, tremor, blurred vision,  
abnormal taste sensations, paraesthesia**

**3- heart failure due to -ve inotropic effect**

# CLASS II DRUGS

## **β- ADRENOCEPTOR BLOCKERS**

**pharmacological actions :**

**block  $\beta_1$ - receptors in the heart**



**reduce the sympathetic effect on the heart**



- 1 - decrease automaticity of S.A. node and ectopic pacemakers**
- 2 - prolong refractory period ( slow conduction ) of the A.V node**



# CLASS II DRUGS

## **β-ADRENOCEPTOR BLOCKERS**

### **Therapeutic uses :**

**1- atrial arrhythmias associated with emotion:**

- e.g. :**
- after exercise**
  - thyrotoxicosis**

**2- WPW**

**3- digitalis-induced arrhythmias**

# CLASS II DRUGS

## $\beta$ -ADRENOCEPTOR BLOCKERS

**Therapeutic uses :**

### **Esmolol :**

- very short acting ( half-life = 9 min. )
- given I.V. for rapid control of ventricular rate in patients with atrial flutter or fibrillation

### **Propranolol, Atenolol, Metoprolol :**

- used in patients who had myocardial infarction to reduce incidence of sudden death due to ventricular arrhythmias

## CLASS III DRUGS

- **Prolong the action potential duration and refractory period**
- **Prolong phase 3 repolarization**

Class III drugs prolong  
Phase 3 repolarization,  
without altering Phase 0.



# CLASS III DRUGS

## AMIODARONE

### pharmacological actions :

- prolongs action potential duration and therefore prolongs refractory period ( **Main effect** )
  - additional class Ia, II & IV effects
  - vasodilating effects
- ( due to its  $\alpha$ - &  $\beta$ -adrenoceptor blocking effects and its calcium channel blocking effects )

# CLASS III DRUGS

## AMIODARONE

### Therapeutic uses :

- 1- main use : serious resistant ventricular arrhythmias
- 2- maintenance of sinus rhythm after cardioversion
- 3- resistant supraventricular arrhythmias ( e.g. WPW )

# CLASS III DRUGS

## AMIODARONE

### Adverse effects:

- exacerbation of ventricular arrhythmias  
( with high dose)
- bradycardia and heart failure
- pulmonary fibrosis
- hyper- or hypothyroidism
- photodermatitis & skin deposits  
( patients should avoid exposure to the sun)



## CLASS III DRUGS

### AMIODARONE

#### Adverse effects:

- Neurological:
  - e.g. tremors and peripheral neuropathy
- nausea, vomiting and constipation
- corneal micro deposits
- hepatocellular necrosis

# CLASS III DRUGS

## AMIODARONE

### Pharmacokinetics:

- extremely long  $t_{1/2} = 13 - 103 \text{ DAYS}$
- metabolized by CYP3A4 and CYP2C8 to its major  
active metabolite: **N-desethylamiodarone**
- eliminated primarily by hepatic metabolism
- cross placenta and appear in breast milk

# CLASS III DRUGS

## AMIODARONE

### Drug Interactions:

1 - Co-administration of amiodarone with drugs that prolong the QT interval increases the risk of Torsades de Points

e.g. :

macrolide antibiotics ( Clarithromycin, Erythromycin)

azole antifungals (Ketoconazole)

# CLASS III DRUGS

## AMIODARONE

### Drug Interactions:

- 2- Drugs (or substances) that **inhibit** these enzymes  
Cause increase in serum concentration of amiodarone  
**e.g. : Loratadine, Ritonavir , Trazodone**  
**Cimetidine, Grapefruit juice**
  
- 3- Drugs that induce these enzymes  
Cause decrease in serum concentration of amiodarone  
**e.g. : Rifampin**

# **PURE CLASS III**

## **Ibutilide**

- **Given by rapid I.V. infusion**
- **Used for the acute conversion of atrial flutter or fibrillation to normal sinus rhythm**
- **Causes QT interval prolongation**  
**( may cause torsades de pointes )**

# **Class 1V**

## **calcium channel blockers**

### **Verapamil, Diltiazem**

- **main site of action is A.V.N & S.A.N**  
**cause:**
  - **slowing of conduction**
  - **prolongation of effective refractory period**

# Class 1V calcium channel blockers

## Therapeutic uses :

- 1- atrial arrhythmias
- 2- re-entry supraventricular arrhythmias  
e.g. WPW
- 3- NOT effective in ventricular arrhythmias



# ADENOSINE

## Mechanism of action :

- inhibits cAMP by binding to adenosine **A1** receptors causing the following actions:

1 - opening of potassium channels


(hyperpolarization)

2 - decreasing conduction velocity mainly at AV node

( negative dromotropic effect )

3- inhibiting phase 4 pacemaker action potential at SA node

( negative chronotropic effect )



# ADENOSINE

## Therapeutic uses :

- drug of choice for acute management of paroxysmal supraventricular tachycardia

- preferred over verapamil

(safer and does not depress contractility)

**half-life = less than 10 sec**

# ADENOSINE

## Adverse effects:

- flushing in about 20% of patients
- shortness of breath and chest burning in 10% of patients ( due to bronchospasm )
- brief AV block (contraindicated in heart block)

# **New Antiarrhythmic Drugs**

## **Dronedarone**

- **a noniodinated congener of amiodarone**
- **has antiarrhythmic properties belonging to all four classes**
- **Used for maintenance of sinus rhythm following cardioversion in patients with atrial fibrillation**

# New Antiarrhythmic Drugs

## Dronedarone

### WARNINGS

- should **not** be used in patients with severe (class IV) heart failure. Risk of death may be increased in these patients.
- should **not** be used in patients with permanent atrial fibrillation. Risk of death and stroke, may be increased in these patients.

# BRADYARRHYTHMIAS

## ATROPINE


- used in sinus bradycardia after myocardial infarction and in heart block
- in emergency heart block **isoprenaline** may be combined with atropine (**caution**)



# NONPHARMACOLOGIC THERAPY OF ARRHYTHMIAS

## Implantable Cardiac Defibrillator (ICD)

- can automatically detect and treat fatal arrhythmias such as ventricular fibrillation



Thank you

